Seegene signs license deal with BioMérieux, 10/13
Seegene announced that BioMérieux has licensed the company’s DPO and TOCE technologies for the development of multiplexed tests for food safety.
Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Benchtop lead analyzer, 10/13
Magellan Diagnostics has received FDA 510(k) clearance to market its LeadCare Ultra benchtop blood lead testing system in the United States.
Wipes minimize cross-contamination, 10/13
Current Technologies’ Bio-Hazard wipes protect patients and employees from cross-contamination when opening and handling specimen containers and sputum cups. The white side of the Bio-Hazard wipe absorbs specimen contents and sputum, while the orange plastic backing prevents splash or leakage from containers to gloves.
Horizon licenses technology from Sigma-Aldrich, 10/13
Horizon Discovery has entered into a nonexclusive license agreement with Sigma-Aldrich for use of its CompoZr zinc finger nuclease (ZFN) technology.
New molecular test for Trichomonas vaginalis, 10/13
BD Diagnostics announced FDA clearance of its BD ProbeTec Trichomonas vaginalis Qx amplified DNA assay for the direct qualitative detection of T. vaginalis DNA in endocervical samples, vaginal samples, and neat urine specimens. This assay, developed to aid in the diagnosis of trichomoniasis, has been CE marked to the in vitro diagnostic directive.
SeraCare acquires KPL, 10/13
SeraCare Life Sciences has acquired Kirkegaard & Perry Laboratories (KPL), a provider of antibodies and related reagents for the diagnostic and life sciences markets.
Collaboration expands access to peanut allergy tests, 10/13
Thermo Fisher Scientific’s ImmunoCAP peanut component tests are now available through Quest Diagnostics. Unlike skin scratch testing, the ImmunoCAP peanut component tests measure a patient’s IgE sensitization to five individual peanut proteins, or allergen components.
Positive coverage decision for metastatic cancer test, 10/13
BioTheranostics, a provider of molecular diagnostic solutions for cancer, has received a positive coverage decision and in-network provider status from Tufts Health Plan for its CancerType ID molecular cancer classifier. CancerType ID predicts tumor type in patients with metastatic cancers.
Educational resources from Diagnostica Stago, 10/13
Diagnostica Stago offers expertise through two free electronic resources to educate health care professionals about hemostasis and thrombosis. The Stago-EdVantage Web site and iHemOStasis app for the Apple iPad offer ways to increase hemostasis knowledge; understand clinical situations, therapies, and detection methods; and apply practical skills to patient care.
Natera to continue using Illumina’s HiSeq 2500, 10/13
Illumina and Natera announced they have entered into a three-year agreement whereby Illumina will supply Natera with the HiSeq 2500 sequencing system and associated consumables for performing Natera’s noninvasive prenatal test (NIPT) Panorama.